Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000188 · ClinicalTrials.gov registry record · Phase 2
Selegiline in Treatment of Cocaine Dependence - 2
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00000188: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00000188 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000188, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.
Interventions
- DRUG Selegiline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1994-09 |
| Est. Completion | 1995-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000188
The ClinicalTrials.gov registry entry for NCT00000188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selegiline is the first listed.
NCT00000188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000188 about?
NCT00000188 is a clinical study titled "Selegiline in Treatment of Cocaine Dependence - 2". The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.
What is the current status of trial NCT00000188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1994-09. Estimated completion is 1995-10.
What interventions are being tested in trial NCT00000188?
The interventions under investigation include: Selegiline (DRUG).
Who is sponsoring clinical trial NCT00000188?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.